Revolution Medicines doses first patient in trial evaluating RMC-5127

Revolution Medicines (RVMD) announced the first patient was dosed in its first-in-human clinical trial evaluating RMC-5127, a RAS G12V-selective inhibitor. The first-in-human trial, RMC-5127-001, is an open-label trial evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of RMC-5127 as both a monotherapy and in combination settings. The trial will enroll patients with RAS G12V-mutated solid tumors, including pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer, who have progressed on or are intolerant to prior standard therapies, including targeted treatments.